Ontology highlight
ABSTRACT:
SUBMITTER: Guerra VA
PROVIDER: S-EPMC6535741 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Therapeutic advances in hematology 20190519
Adult acute lymphoblastic leukemia (ALL) has a poor overall survival compared with pediatric ALL where cure rates are observed in more than 90% of patients. The recent development of novel monoclonal antibodies targeting CD20, CD19, and CD22 has changed the long-term outcome of this disease, both in the frontline setting (e.g. rituximab) and for patients with relapsed/refractory disease (e.g. inotuzumab ozogamicin and blinatumomab). The CD3-CD19 bispecific T-cell-engaging antibody blinatumomab i ...[more]